




**The effect of dose on the antimalarial
efficacy of artemether-lumefantrine: a
systematic review and pooled analysis of
individual patient data**

WWARN AL Dose Impact Study Group*

Study Groups → Collaborations

Define Scientific Question



Bring together Collaborative Partnership



Agree on Analytical Plan



Collate Data in WWARN Format




Meta-analysis : Power, Temporal & Geographic variation



Joint Publication with Open Access to additional material

Data processing



Artemether lumefantrine (AL)

Dose Impact Study Group

- **Objectives**
 - Determine mg/kg distribution of AM and LUM
 - Investigate influence of mg/kg dosing on early and late parasitological response
 - Identify major risk factors associated with treatment failure
 - Assess relationships between dose and tolerability

Methodology

- Literature Review to identify all published studies
- Active search of unpublished studies
- Data compiled and standardised
 - <http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf>
- A priori Analytical Plan
 - Weight adjusted drug dosage calculated using
 - Tablet counts where available
 - Back calculation from study protocol (weight/age)
 - Survival analysis
 - Cox proportional hazards model with shared frailties to account for heterogeneous study sites
 - Population attributable risks (PARs) associated with recrudescence failures
 - Relationship between drug dose and gastrointestinal side effects explored using logistic regression with random effects fitted for individual study & sites

AL Dose impact study group sites


- 53 published studies (n=12,586) & 8 unpublished studies (n=1741)
- 14,327 patients between 1998–2012



Baseline characteristics

	Asia	Africa	South America	Overall
N	2359 (16.5%)	11809 (82.4%)	159 (1.1%)	14327
Study period	1998-2010	2002-2012	2007-2008	1998-2012
Age (years)				
Median age [Range]	16.0 [0.5-77]	3.5 [0-77]	23.0 [12-56]	4.0 [0-80]
<1	0.3%	6.9%	0.0%	5.7%
1 to <5	15.81%	58.9%	0.0%	51.2%
5 to <12	21.3%	21.0%	0.0%	20.8%
≥ 12	62.6%	13.2%	100.0%	22.3%
Treatment supervision				
Full	77.3%	76.9%	100.0%	77.3%
Drug trade name				
Coartem® (Novartis)	100.0%	94.2%	100.0%	95.2%
Enrolment clinical variables				
Median parasitaemia (parasites/μl) [IQR]	9559 [13-450440]	21360 [16-420360]	4241 [1008-44744]	19921 [13-450440]
Children underweight for age (UWA)	36.7%	17.3%	-	18.4%

Dosing of lumefantrine and efficacy



Dosing implications for AL efficacy

Patients with low AM daily dose:

Greater Risk of Parasitaemia on day 1

Patients with low AM total dose:

Greater Risk of gametocyte carriage on day 14

	Kaplan-Meier Survival Estimates	
	Day 28 n=11,923	Day 42 n=4,279
Overall	97.6 %	96.0 %
Age group (years)		
<1	97.0 %	95.2 %
1 to 3 (underweight)	94.3 %	92.5 %
1-3	96.8 %	95.1 %
3 to 5 (underweight)	98.1 %	94.7 %
3 to 5	97.2 %	94.1 %
5 to <12	98.4 %	97.3 %
≥12	98.9 %	98.3 %
Region		
Africa	97.5 %	95.4 %
Asia	98.0 %	97.5 %
S America	99.4 %	98.7 %



Risk factors for recrudescence and PARs

	Multivariable Analysis		Population attributable risks (PARs)	
	Adjusted HR [95% CI]	p-Value	Freq.	PARs
Lumefantrine dose (every 5 mg/kg increase)	0.98 [0.94-1.02]	0.380	27.46%	6.30%
Enrolment clinical variables				
Parasitemia (log scale)	1.41 [1.15-1.74]	0.001	9.51%	4.01%
Age category (years)				
≥ 12 (reference)				
<1	1.78 [0.89-3.55]	0.100	5.72%	4.76%
1 to <5	2.00 [1.23-3.23]	0.005	51.14%	37.92%
5 to <12	1.27 [0.76-2.12]	0.360	20.79%	7.96%

Overall PAR for model: 54.1 %


However, interaction between region, parasitemia and LUM dose

Africa vs Asia



In Asia, the LUM dose associated with recrudescence

Africa



Malnutrition associated with
recrudescence in Africa

Conclusions

- AL is highly effective in most of patients
- Cure rates were lowest in young children from Asia, especially those with high parasitemia and young underweight children from Africa
- A higher dose regimen should be evaluated in these groups, especially in young patients between 13 and 15kg

AL Dose impact study group members*

• Salim Abdulla	• Stephan Duparc	• Erasmus Kamugisha	• Frederic Nikiema	• Khadime Sylla
• Jane Achan	• Emmanuelle Espié	• Moses R Kamya	• Francois Nosten	• Ambrose O Talisuna
• Ishag Adam	• Abul M Faiz	• Corine Karema	• Christian Nsanzabana	• Emiliana Tjitra
• George O Adjei	• Catherine O Falade	• Harin A. Karunajeewa	• Mary Oguike	• Roger CK Tine
• Bereket H Alemayehu	• Jean-François Fauch	• Maniphone Khanthavong	• Bernhards R Ogutu	• Halidou Tinto
• Paul Aliu	• Babacar Faye	• Fred Kironde	• Piero OlliaroSabah A Omar	• Offianan A Toure
• Emmanuel Arinaitwe	• Oumar Faye	• Poul-Erik Kofoed	• Jean-Bosco Ouédraogo	• Johan Ursing
• Elizabeth A Ashley	• Scott Filler	• Moussa Kone	• Louis K Penali	• Ingrid van den Broek
• Mamadou S Ba	• Jennifer A Flegg	• Ibrahim Maman Laminou	• Mbaye Pene	• Michele Van Vugt
• Suna Balkan	• Bakary Fofana	• Sue J Lee	• Judy Peshu	• Stephen A Ward
• Karen I Barnes	• Nahla B Gadalla	• Bertrand Lell	• Loretxu Pinoges	• Nicholas J White
• Quique Bassat	• Oumar Gaye	• Angeles Lima	• Patrice Piola	• Peter A Winstanley
• Elizabeth Baudin	• Blaise Genton	• ElFatih M Malik	• Zul Premji	• William Yavo
• Anders Björkman	• Peter W Gething	• Kevin Marsh	• Ric N Price	• Adoke Yeka
• Steffen Borrmann	• José P Gil	• Andreas Mårtensson	• Philip J Rosenthal	• Issaka Zongo
• Teun J Bousema	• Raquel González	• Achille Massougbodji	• Issaka Sagara	• MMV
• Hasifa Bukirwa	• Bryan Greenhouse	• Mayfong Mayxay	• Albert Same-Ekobo	• Novartis
• Verena Ilona Carrara	• Brian Greenwood	• Rose McGready	• Patrick Sawa	
• Francesco Checchi	• Anastasia Grivoyannis	• Hervé Menan	• Henk DFH Schallig	
• Michel Cot	• Philippe J Guerin	• Clara Menéndez	• Birgit Schramm	
• Prabin Dahal	• Jean-Paul Guthman	• Petra F Mens	• Seif A Shekalaghe	
• Umberto D'Alessandro	• Kamal Hamed	• Martin Meremikwu	• Carol Hopkins Sibley	
• Timothy ME Davis	• Simon I Hay	• Clarissa Moreira	• Jeff Smith	
• Philippe Deloron	• Eva Maria Hodel	• Ivo Mueller	• Frank Smithuis	
• Abdoulaye A Djimde	• Jimée Hwang	• Carolyn Nabasumba	• Doudou Sow	
• Arjen M Dondorp	• Daddi Jima	• Michael Nambozi	• Sarah G Staedke	
• Grant Dorsey	• Elizabeth Juma	• Jean-Louis Ndiaye	• Kasia Stepniewska	
• Ogobara K Doumbo	• Patrick S Kachur	• Paul N Newton	• Colin J Sutherland	
• Chris J Drakeley	• Piet A Kager	• Billy E Ngasala	• Göte Swedberg	

WWARN Team

- **WWARN regional centres:** Ambrose O. Talisuna, Rachel Ochola, Louis K. Penali, Amadou Seck, Penda Touré, Jeffery Smith, Jessica Fried, Ligia Goncalves
- **Data management:** Clarissa Moreira and Georgina S. Humphreys
- **Statistical analysis:** Prabin Dahal, Kasia Stepniewska
- **Analysis and Writing:** Christian Nsanzabana, Carol H. Sibley, Karen I. Barnes, Joel Tarning, Philippe J. Guerin and Ric N. Price

References

- Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. *The Lancet Infectious Diseases* 2015; D-14-00566R1; DOI [10.1016/S1473-3099\(15\)70024-1](https://doi.org/10.1016/S1473-3099(15)70024-1)
- [WWARN newsletter article](#)



www.wwarn.org

info@wwarn.org

twitter.com/WWARN

www.facebook.com/AntimalarialResistance